The American Society of Retinal Specialists (ASRS) issued a warning letter about the Syfovre occlusive retinal vasculitis cases in patients who used this injection eye drug. Syfovre is a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Occlusive retinal vasculitis is a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and could potentially cause blindness.
This ASRS July 2023 letter about Syfovre occlusive retinal vasculitis cases pointed out that the vision loss symptoms began one to two weeks after a patient’s first Syfovre (pegcetacoplan) injection. The ASRS said there have been six reports of occlusive retinal vasculitis to date, as well as other reports of serious eye inflammation due to Syfovre injections.
Back in 2020, the ASRS alerted its member doctors about 14 cases of retinal vasculitis in patients after using Beovu, soon after that wet age-related macular degeneration drug from Novartis was approved by the FDA.
During the past couple of years, our law firm handled Beovu lawsuits for vision loss, blindness, and other serious eye problems that were filed against Novartis, the manufacturer of Beovu.
We are investigating Syfovre drug injury lawsuits against Apellis Pharmaceuticals, Inc., the drug company responsible for Syfovre, for patients who developed occlusive retinal vasculitis, eye inflammation, vision loss, or blindness after receiving Syfovre injections.
If you or someone you know has a possible Syfovre drug injury lawsuit, we encourage you to submit a Case Evaluation Form online.[Read article in full at original source]
Strictly Confidential, No Obligation